Rafat Abonour, Professor at University of Miami Miller School of Medicine, shared on LinkedIn:
“Ahead of ASH26, several pivotal interventional trials in Multiple Myeloma and AL Amyloidosis are poised to reshape clinical practice—from MRD-guided treatment de-escalation and precursor interception to abbreviated bispecific consolidation and CAR-T.
Excited to share my Top 10 interventional abstracts with colleagues at the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine:
1. PERSEUS (6.8-year follow-up): DVRd-DR demonstrates durable OS (HR 0.57) and 6-year PFS (81.1%), validating MRD-guided daratumumab discontinuation (91.4% 48-month post-landmark PFS).
2. AQUILA (7.4-year follow-up): Fixed-duration subcutaneous daratumumab in high-risk smoldering MM cuts the risk of death by 48% (HR 0.52) and delays progression by ~4 years without blunting subsequent first-line therapy.
3. EXCALIBER-RRMM: Iberdomide + daratumumab + dexamethasone (IberDd) doubles MRD-negative CR rates vs. DVd (41.1% vs. 20.7%) at first relapse.
4. BENEFIT (48-month follow-up): Isa-VRd reinforces quadruplet standard of care in transplant-ineligible NDMM (48-month PFS 74% vs. 65.7%; high-risk MM 63.1% vs. 40.2%).
5. NEXICART-2: NXC-201 BCMA CAR-T delivers 100% ongoing CR (>12-month follow-up) and 100% cardiac and renal organ responses in relapsed/refractory AL amyloidosis.
6. IMMUNOPLANT (Paper 417): Abbreviated fixed-duration (4–6 cycles) linvoseltamab consolidation in MRD-positive NDMM post-induction achieves 91.9% NGS MRD negativity (10^-6), 100% 1-year sustained MRD negativity (10/10), and 0% CRS/ICANS as a potential alternative to upfront ASCT.
7. MajesTEC-5 (Arm G): Frontline trispecific ramantamig + daratumumab + lenalidomide achieves a 100% ORR and 100% MRD negativity (10^-5) by Cycle 3 in transplant-eligible NDMM.
8. GEM-AnitoFIRST: Frontline anitocabtagene autoleucel following quadruplet induction yields 100% MRD negativity (10^-6) by Day +60 with 0% ICANS.
9. REVIVE: Fixed-duration (24-month) teclistamab + daratumumab in high-risk smoldering MM achieves 100% MRD negativity (10^-6) in evaluable CRs with 0% CRS or ICANS.
10. BMS-986453: Dual-targeting BCMA×GPRC5D CAR-T reaches a 94% ORR (89% in prior-BCMA exposed; 93% 12-month PFS in naïve patients) in RRMM.
Which of these readouts do you think will have the most immediate impact on patient care? I say our owns.”
You can also read: ASH 2026 Myelofibrosis Guidelines: New Recommendations for JAK Inhibitors, Anemia and Transplantation
